Publications by the researcher in collaboration with JOAQUÍN MARÍA CAMPOS ROSA (28)

2012

  1. The selective cytotoxic activity in breast cancer cells by an anthranilic alcohol-derived acyclic 5-fluorouracil O,N-acetal is mediated by endoplasmic reticulum stress-induced apoptosis

    European Journal of Medicinal Chemistry, Vol. 50, pp. 376-382

2011

  1. Anticancer activity and cDNA microarray studies of a (RS)-1,2,3,5- tetrahydro-4,1-benzoxazepine-3-yl]-6-chloro-9H-purine, and an acyclic (RS)-O,N-acetalic 6-chloro-7H-purine

    European Journal of Medicinal Chemistry, Vol. 46, Núm. 9, pp. 3802-3809

  2. New (RS)-benzoxazepin-purines with antitumour activity: The chiral switch from (RS)-2,6-dichloro-9-[1-(p-nitrobenzenesulfonyl)-1,2,3,5-tetrahydro-4,1- benzoxazepin-3-yl]-9H-purine

    European Journal of Medicinal Chemistry, Vol. 46, Núm. 1, pp. 249-258

  3. Synthesis and Anticancer Activity of the (R,S)-Benzofused 1,5-Oxathiepine Moiety Tethered to Purines through Alkylidenoxy Linkers

    ChemMedChem, Vol. 6, Núm. 10, pp. 1854-1859

  4. Synthesis and anticancer activity of (RS)-9-(2,3-dihydro-1,4- benzoxaheteroin-2-ylmethyl)-9H-purines

    European Journal of Medicinal Chemistry, Vol. 46, Núm. 9, pp. 3795-3801

  5. The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53- independent manner in colon and breast cancer cells

    PLoS ONE, Vol. 6, Núm. 8

2009

  1. Acyclonucleosides, modified seco-nucleosides, and salicyl- or catechol-derived acyclic 5-fluorouracil O,N-acetals: Antiproliferative activities, cellular differentiation and apoptosis

    Current Medicinal Chemistry, Vol. 16, Núm. 9, pp. 1166-1183

2008

  1. Anticancer activity of (1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl)-pyrimidines and -purines against the MCF-7 cell line: Preliminary cDNA microarray studies

    Bioorganic and Medicinal Chemistry Letters, Vol. 18, Núm. 4, pp. 1457-1460

  2. Regiospecific microwave-assisted synthesis and cytotoxic activity against human breast cancer cells of (RS)-6-substituted-7- or 9-(2,3-dihydro-5H-1,4-benzodioxepin-3-yl)-7H- or -9H-purines

    European Journal of Medicinal Chemistry, Vol. 43, Núm. 8, pp. 1742-1748

  3. Synthesis and anticancer activity of (R,S)-9-(2,3-dihydro-1,4-benzoxathiin- 3-ylmethyl)-9H-purines

    ChemMedChem, Vol. 3, Núm. 1, pp. 127-135

2007

  1. 5-fluorouracil derivatives induce differentiation mediated by tubulin and HLA class I modulation

    Medicinal Chemistry, Vol. 3, Núm. 3, pp. 233-239

  2. 6′-Chloro-7- or 9-(2,3-dihydro-5H-4,1-benzoxathiepin-3-yl)-7H- or 9H-purines and their corresponding sulfones as a new family of cytotoxic drugs

    Tetrahedron, Vol. 63, Núm. 1, pp. 183-190

  3. A synthetic uracil derivative with antitumor activity through decreasing cyclin D1 and Cdk1, and increasing p21 and p27 in MCF-7 cells

    Breast Cancer Research and Treatment, Vol. 105, Núm. 3, pp. 237-246

  4. Antiproliferative activity, cell-cycle dysregulation, and cellular differentiation: Salicyl- and catechol-derived acyclic 5-fluorouracil O,N-acetals against breast cancer cells

    ChemMedChem, Vol. 2, Núm. 12, pp. 1814-1821

2006

  1. Differentiation: An encouraging approach to anticancer therapy

    Italian Journal of Anatomy and Embryology, Vol. 111, Núm. 1, pp. 45-64

  2. Synthesis and anticancer activity studies of novel 1-(2,3-dihydro-5H-1,4-benzodioxepin-3-yl)uracil and (6′-substituted)-7- or 9-(2,3-dihydro-5H-1,4-benzodioxepin-3-yl)-7H- or 9H-purines

    Tetrahedron, Vol. 62, Núm. 50, pp. 11724-11733

2005

  1. Antitumoural properties of benzannelated seven-membered 5-fluorouracil derivatives and related open analogues. Molecular markers for apoptosis and cell cycle dysregulation

    Farmaco

  2. New medium oxacyclic O,N-acetals and related open analogues: Biological activities

    Current Medicinal Chemistry, Vol. 12, Núm. 12, pp. 1423-1438

  3. Synthesis of novel 1-(2,3-dihydro-5H-4,1-benzoxathiepin-3-yl)-uracil and -thymine, and their corresponding S-oxidized derivatives

    Tetrahedron, Vol. 61, Núm. 43, pp. 10363-10369

2004

  1. Actual targets in cytodifferentiation cancer therapy

    Current Topics in Medicinal Chemistry, Vol. 4, Núm. 2, pp. 175-202